Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Combination immunotherapy shows over 50% long-term disease control in melanoma patients with brain metastases.
A new study shows that a combination of immunotherapy drugs can significantly improve survival rates for melanoma patients with cancer that has spread to the brain.
The seven-year follow-up of a clinical trial revealed that over 50% of patients treated with this combination achieved long-term disease control.
This is a major improvement from the previous 16-week survival rate.
The study, published in the Lancet Oncology, suggests that combination immunotherapy should become the standard treatment for such patients.
15 Articles
La inmunoterapia combinada muestra más del 50% de control de la enfermedad a largo plazo en pacientes con melanoma con metástasis cerebrales.